New pill better targets rheumatoid arthritis

In November 2012 the FDA approved a new treatment for people with rheumatoid arthritis called tofacitinib (Xeljanz). Unlike previous biologic treatments, the new drug is a pill, not an injection, and it targets another type of inflammatory molecule.